ABC | Volume 113, Nº4, Outubro 2019

Atualização Atualização da Diretriz de Prevenção Cardiovascular da Sociedade Brasileira de Cardiologia – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 99. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. 100. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. 101. Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39(27):2540-5. 102. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57(16):1666-75. 103. ASCENDStudyCollaborativeGroup,BowmanL,MafhamM,Wallendszus K, Stevens W, Buck G, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529-39. 104. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double- blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. 105. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509-18. 106. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participantdatafromrandomisedtrials.Lancet.2009;373(9678):1849-60. 107. Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7(3):453-60. 108. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all causemortality, cardiovascular death, andmicrovascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul;343:d4169. 109. Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. 110. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. 111. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-29. 112. PeñaM, Bacallao J. La obesidad en la pobreza: un nuevo reto para la salud pública. Washington (DC): OPAS; 2000. 113. Instituto Brasileiro de Geografia e Estatística. (IBGE) [Internet]. Pesquisa Nacional de Saúde 2013. [acesso em 1 jan 2009]. Disponível em: ftp:// ftp.ibge.gov.br/PNS/2013/ pns2013. 114. Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al. The global syndemic of obesity, undernutrition, and climate change: the Lancet Commission report. Lancet. 2019;393(10173):791-846. 115. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9945):766-81. 116. Brasil. Ministerio da Saude. Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico. Vigitel 2014. Brasília; 2014. 117. Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Analise em Saude e Vigilancia de Doencas nao Transmissiveis. Vigitel Brasil 2018: vigilancia de fatores de risco e proteço para doencas cronicas por inquerito telefonico : estimativas sobre frequencia e distribuiço sociodemografica de fatores de risco e proteço para doencas cronicas nas capitais dos 26 estados brasileiros e noDistrito Federal em2018 / Ministerio da Saude, Secretaria de Vigilancia em Saude, Departamento de Analise em Saude e Vigilancia de Doencas nao Transmissiveis. – Brasilia: Ministerio da Saude, 2019. 118. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007 Jun;29:1-5. 119. Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, et al. Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019;25(5):380-400. 120. Pouwels S, Topal B, Knook MT, Celik A, Sundbom M, Ribeiro R, et al. Interaction of obesity and atrial fibrillation: an overview of pathophysiology and clinical management. Expert Rev Cardiovasc Ther. 2019;17(3):209-23. 121. World Health Organization. (WHO) [Internet]. Global strategy on diet, physical activity and health [Cited in 2009 Jan 10]. Available from: http:// www.who.int/gb/ebwha/pdf_files/WHA57/A57_R17-en.pdf. 122. Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28-36. 123. Vergnaud AC, Bertrais S, Oppert JM, Maillard-Teyssier L, Galan P, Hercberg S, et al. Weight fluctuations and risk for metabolic syndrome in an adult cohort. Int J Obes (Lond). 2008;32(2):315-21. 124. StrazzulloP,D’EliaL,CairellaG,GarbagnatiF,CappuccioFP,ScalfiL.Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010;41(5):e418-26. 125. Wakai K, Naito M, Date C, Iso H, Tamakoshi A. Dietary intakes of fat and total mortality among Japanese populations with a low fat intake: the Japan collaborative cohort (JACC) study. Nutr Metab. 2014;11(1):12. 126. World Health Organization. (WHO). Population-based prevention strategies for childhood obesity: report of a WHO Forum and Technical Meeting. Geneva; 2009. 127. NakamuraM, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2019 Mar 14;[Epub ahead of print]. 128. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Mar;pii:S0735-1097(19)33876-8. 129. World Health Organization. (WHO). World Health Statistics 2013. Geneva; 2013. 130. Polak R, Phillips EM, Campbell A. Legumes: health benefits and culinary approaches to increase intake. Clin Diabetes. 2015;33(4):198-205. 131. Lichtenstein AH, Ludwig DS. Bring back home economics education. JAMA. 2010;303(18):1857-8. 132. Kinnunen TI, PasanenM, AittasaloM, FogelholmM, Weiderpass E, Luoto R. Reducing postpartum weight retention - a pilot trial in primary health care. Nutr J. 2007 Sep;6:21. 133. Sichieri R, Souza RA. Strategies for obesity prevention in children and adolescents. Cad Saúde Pública. 2008;24(Suppl 2):S209-23. 134. Arenz S, Rückerl R, Koletzko B, von Kries R. Breast-feeding and childhood obesity-a systematic review. Int J Obes Relat Metab Disord. 2004;28(10):1247-56. 876